General
Preferred name
MIRABEGRON
Synonyms
YM178 ()
YM 178 ()
BETANIS ()
Betmiga ()
MYRBETRIQ ()
MYRBETRIQ GRANULES ()
YM-178 ()
P&D ID
PD009179
CAS
223673-61-8
Tags
available
drug
Approved by
FDA
First approval
2012
Drug indication
Overactive bladder
Heart failure
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Mirabegron is a β3-adrenoceptor agonist muscle relaxant. It has been reported to exert effects on cellular metabolism in adipocytes. This latter action is β3-adrenoceptor-dependent, and improves glucose handling in vivo .
(GtoPdb)
ABSORPTION
The absolute bioavailability increases from 29% at a dose of 25 mg to 35% at a dose of 50 mg. Mean Cmax and AUC increase more than dose proportionally. This relationship is more apparent at doses above 50 mg. Females generally have a lower magnitude of increase of Cmax and AUCtau compared to males when doses of mirabegron doubles or quadruples. Steady state concentrations are achieved within 7 days of once daily dosing with mirabegron. After once daily administration, plasma exposure of mirabegron at steady state is approximately double that seen after a single dose.; Tmax, oral dose, healthy subjects= 3.5 hours;
DESCRIPTION
Mirabegron is a selective ¦Â3-adrenoceptor agonist with EC50 of 22.4 nM.
PRICE
70
DESCRIPTION
Mirabegron is a beta-3 adrenergic agonist. It is used to treat overactive bladder and neurogenic detrusor overactivity.
(Enamine Bioactive Compounds)
DESCRIPTION
Potent CCR4 antagonist
(Tocris Bioactive Compound Library)
DESCRIPTION
Mirabegron (YM178) is a beta-3 adrenergic agonist that is used for treatment of overactive bladder syndrome.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
28
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
EU-OPENSCREEN Bioactive Compound Library
EUbOPEN Chemogenomics Library
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
174
Molecular Weight
396.16
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
4
Rotatable Bonds
9
Ring Count
3
Aromatic Ring Count
3
cLogP
2.77
TPSA
100.27
Fraction CSP3
0.24
Chiral centers
1.0
Largest ring
6.0
QED
0.42
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Adrenergic Receptor
β3-adrenoceptor
ADRB1, ADRB2, ADRB3
ß3 agonist
Primary Target
Adrenergic ?3 Receptors
MOA
Agonist
Adrenergic Receptor agonist
Indication
urinary incontinence
Pathway
GPCR/G protein
Neuroscience
Neuronal Signaling
Recommended Cell Concentration
None
Source data
